Picture of Madrigal Pharmaceuticals logo

MDGL — Madrigal Pharmaceuticals News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapMomentum Trap

Madrigal Pharmaceuticals Inc reports results for the quarter ended in September 30 - Earnings Summary

* Madrigal Pharmaceuticals Inc  MDGL.OQ  reported a
quarterly
adjusted loss of $4.92​​ per share for the quarter ended
September 30, higher than the same quarter last year, when the
company reported EPS of $-5.34.  The mean expectation of
fifteen analysts for the quarter was for a loss of $6.91 per
share. Wall Street expected results to range from $-8.45
to $-6.28 per share.
    * Revenue was $62.18 million​; analysts expected $34.19
million. 
    * Madrigal Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of $4.92​.
    * The company reported a quarterly loss of $106.96 million.
    * Madrigal Pharmaceuticals Inc shares had risen by 1.7% this
quarter and lost 6.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 1.9%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," 3
"hold" and 1 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Madrigal
Pharmaceuticals Inc is $390.00 
This summary was machine generated from LSEG data November 1 at
03:50 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -6.91          -4.92          Beat
 Jun. 30 2024      -7.53          -7.10          Beat
 Mar. 31 2024      -6.28          -7.38          Missed
 Dec. 31 2023      -5.28          -5.68          Missed

Recent news on Madrigal Pharmaceuticals

See all news